B cell chronic lymphocytic leukaemia cells have reduced capacity to upregulate expression of MHC class I in response to interferon-γ
Authors:
Helen Juffs a;
Nina Fowler a;
Russell Saal b;
Karen Grimmett b;
Shannon Beasley a;
Brendan O'Sullivan a;
Ian Frazer a;
Devinder gill b;
Ranjeny Thomas a
| Affiliations: | a Centre for Immunology and Cancer Research, University of Queensland, Qld |
| b Division of Haematology, Princess Alexandra Hospital, Brisbane, Qld, Australia |
DOI:
10.1080/00313020310001644499
Publication Frequency:
7 issues per year
Subject:
Pathology;
Number of References: 38
Formats available:
PDF
(English)
View Article:
View Article (PDF)
Abstract
Aims: An important consideration in the design of a tumour vaccine is the ability of tumour-specific cytotoxic T lymphocytes (CTL) to recognise unmanipulated tumour cells in vivo. To determine whether B-CLL might use an escape strategy, the current studies compared B-CLL and normal B cell MHC class I expression.
Methods: Flow cytometry, TAP allele PCR and MHC class I PCR were used. Results: While baseline expression of MHC class I did not differ, upregulation of MHC class I expression by B-CLL cells in response to IFN-γ was reduced. No deletions or mutations of TAP 1 or 2 genes were detected. B-CLL cells upregulated TAP protein expression in response to IFN-γ. Responsiveness of B-CLL MHC class I mRNA to IFN-γ was not impaired. Conclusions: The data suggest that MHC class I molecules might be less stable at the cell surface in B-CLL than normal B cells, as a result of the described release of β2m and β2m-free class I heavy chains from the membrane. This relative MHC class I expression defect of B-CLL cells may reduce their susceptibility to CTL lysis in response to immunotherapeutic approaches. |
| Keywords: Human; B-CLL; antigen presentation; MHC class I; TAP |
| view references (38) |


Download Citation
CiteULike
Del.icio.us
BibSonomy
Connotea